8-K: ResMed Sells MatrixCare Business for $490M

ResMed Inc. announced an agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction, aiming to sharpen its focus on sleep and connected care markets.

Summary

• ResMed Inc. has entered into a definitive agreement to sell its MatrixCare business, which provides software solutions for skilled nursing, senior living, long-term care, life planning communities, and home health and hospice, to Frazier Healthcare Partners.
• The transaction is an all-cash deal valued at $490 million, subject to closing adjustments.
• The sale is expected to close in the first quarter of ResMed's fiscal year 2027, pending regulatory approvals and customary closing conditions.
• ResMed plans to use the net proceeds to return capital to shareholders, including an accelerated share repurchase program, and for general corporate purposes.
• Transition services agreements (TSAs) will be put in place to ensure operational continuity, with TSAs largely offsetting stranded costs in the first year post-closing.
• The MatrixCare business represented approximately $220 million in revenue and $55 million in non-GAAP operating profit for the full fiscal year 2026.
• ResMed's recently acquired Noctrix business is expected to add approximately $30 million in revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal year 2027.
• The company reiterates its fiscal year 2026 outlook for non-GAAP gross margin, SG&A, R&D, and tax rate, as well as its fourth quarter fiscal year 2026 outlook for net interest income and share repurchases.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the strategic focus on core high-growth markets and the significant capital infusion from the sale, though the EPS dilution from Noctrix is a minor concern.

Positives

• Divestiture of MatrixCare business for $490 million in all-cash transaction, providing capital for shareholder returns and strategic initiatives.
• Sharpened focus on high-growth sleep and connected care markets aligns with ResMed's 2030 strategy.
• Reallocation of capital and resources towards innovation, operational scale, and long-term value creation.
• Expected to largely offset stranded costs in the first year post-closing through transition services agreements.
• Frazier Healthcare Partners plans to invest aggressively in product innovation for MatrixCare.
• ResMed reiterates its fiscal year 2026 financial outlook, indicating stability in core operations.

Negatives

• The sale of MatrixCare business, which contributed approximately $220 million in revenue and $55 million in non-GAAP operating profit in FY2026.
• The Noctrix acquisition is expected to reduce non-GAAP diluted EPS by approximately $0.20 in fiscal year 2027.

Risks

• The transaction is subject to required regulatory approvals and customary closing conditions, which could delay or prevent the closing.
• Potential for stranded costs to remain beyond the first year post-closing if mitigation efforts are not fully successful.
• Integration risks associated with the Noctrix acquisition and its impact on EPS.
• Future performance of the divested MatrixCare business under new ownership.

Future Outlook

ResMed expects its Residential Care Software (RCS) segment to achieve high single-digit percentage year-over-year revenue growth with operating leverage in fiscal year 2027. The company will provide its full fiscal year 2027 outlook during its fourth quarter fiscal year 2026 earnings call on August 6, 2026. ResMed reiterates its previously provided outlooks for fiscal year 2026 non-GAAP gross margin, SG&A, R&D, tax rate, and fourth quarter fiscal year 2026 net interest income and planned share repurchases.

Management Comments

• "Todays announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth," said Mick Farrell, Chairman and CEO of ResMed.
• "By focusing on areas where we see the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes, and create value for our stakeholders."
• "We are confident MatrixCare and its affiliated businesses will continue to support team members and drive growth under new ownership with a dedicated focus on the long-term care market."
• "Frazier has spent several years evaluating the post-acute care technology sector and believes MatrixCare has established itself as a leading platform serving skilled nursing, senior living, and home health and hospice provider," said Ryan Lucero, General Partner at Frazier Healthcare Partners.
• "We are thrilled to partner with the MatrixCare team and plan to invest aggressively in product innovation to help providers deliver better outcomes as the post-acute care landscape continues to evolve."

Industry Context

StockSavvy.ai notes that ResMed's divestiture of its MatrixCare business aligns with a broader trend of healthcare technology companies focusing on core competencies and divesting non-core assets to drive growth and innovation in specialized high-demand areas like sleep and connected care.

Stakeholder Impact

• Shareholders: Expected positive impact through capital returns via share repurchases and potential long-term value creation from a more focused business strategy.
• Employees: Potential impact on employees of MatrixCare as they transition to new ownership under Frazier Healthcare Partners. ResMed expresses confidence in their continued support and growth.
• Customers: Assurance of continued service and support for MatrixCare customers until the closing of the transaction.
• Suppliers/Creditors: No immediate direct impact mentioned, but long-term financial health of ResMed is expected to be strengthened by strategic focus.

Next Steps

• Close the MatrixCare transaction during the first quarter of ResMed's fiscal year 2027.
• Utilize net proceeds from the sale for shareholder returns (including ASR) and general corporate purposes.
• Provide full fiscal year 2027 outlook during the fourth quarter fiscal year 2026 earnings call on August 6, 2026.
• Continue to operate MatrixCare as part of ResMed until closing, ensuring no changes to customer service or support.

Key Dates

Recommendation

The divestiture of a non-core asset for a significant sum and a renewed focus on core growth areas are positive. However, the expected EPS dilution from the Noctrix acquisition and the need to see the full FY2027 outlook prevent a stronger recommendation. Investors should hold to assess the execution of the new strategy and the impact of acquisitions.

Keywords

ResMed, MatrixCare, Frazier Healthcare Partners, Divestiture, Healthcare Technology, Software Solutions, Sleep Health, Connected Care, Skilled Nursing, Senior Living, Home Health, Hospice, Capital Allocation, Share Repurchase, Regulatory Approval